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The effects of an active vitamin D analog, eldecalcitol (ELD), on bone mineral density 
(BMD), bone geometry, and biomechanical properties of the proximal femur were 
investigated by using clinical CT. The subjects—a subgroup of a recent randomized, 
double-blind study comparing anti-fracture efficacy of ELD with alfacalcidol 
(ALF)—constituted 193 ambulatory patients with osteoporosis (189 postmenopausal women 
and 4 men aged 52–85 years, average±SD: 70.9±6.92 years) enrolled at 11 institutions. 
Multidetector-row CT data was acquired at baseline and at completion of 144 weeks’ 




derived from three-dimensional CT data. Biomechanical properties including cross-sectional 
moment of inertia (CSMI), section modulus (SM) and buckling ratio (BR) of the femoral neck, 
and CSMI of the femoral shaft were also calculated. We found that, 1) with respect to the 
femoral neck cross-sectional parameters (total bone), in the ALF group, volumetric BMD 
(vBMD) decreased but bone mass was maintained and cross-sectional area (CSA) increased. 
In contrast, ELD maintained vBMD with a significant increase in bone mass and a trend 
toward increased CSA. 2) With respect to the femoral neck cross-sectional parameters 
(cortex), cortical thickness decreased in the ALF group, but was maintained in the ELD group. 
In the ALF group, vBMD and bone mass increased, and CSA was maintained. In the ELD 
group, vBMD, CSA, and bone mass increased. 3) With respect to the biomechanical 
properties of the femoral neck, ELD improved CSMI and SM to a greater extent than did ALF. 
BR increased in both the ALF and ELD groups. 4) With respect to the femoral shaft 
parameters, overall the results of bone geometry and CSMI of the femoral shaft were very 
consistent with the results for the femoral neck; however, cortical vBMD of the femoral shaft 
decreased significantly in both the ELD and ALF groups. In conclusion, our longitudinal 
analysis of hip geometry by clinical CT revealed the unexpected potential of ELD to increase 
cortical CSA, vBMD, and bone mass, and to maintain cortical thickness, probably through the 
more potent effect of ELD in mitigating endocortical bone resorption than ALF. By improving 
the biomechanical properties of the proximal femur, ELD may have the potential to reduce the 
risk of hip fractures. 




1.  Introduction 
The incidence of vertebral fracture increases linearly with aging and is significantly correlated 
with declining bone mineral density (BMD). The incidence of hip fracture, on the other hand, 
rises exponentially with aging, suggesting that age-related factors other than BMD contribute 
greatly to the fragility of the proximal femur. Hip fractures cause substantial disability and are 
associated with a high rate of death among elderly women [1]. Because vertebral fracture is 
the most common of osteoporotic fractures, the efficacy of anti-osteoporotic agents is judged 
in clinical trials by evaluating the incidence of vertebral fracture. 
The incidence of hip fracture is much lower than that of vertebral fracture, especially in 
elderly Japanese, and in clinical trials of anti-osteoporotic agents hip fracture is assessed as a 
secondary endpoint or as one of the non-vertebral fractures. However, in view of the 
increasing incidence of hip fracture in the Japanese population [2] and its consequences of 
seriously reducing quality of life (QOL) [3], measures to prevent hip fracture are of 
paramount importance. 
Recently, various imaging techniques have been used to non-invasively estimate the 
effects of intervention on the biomechanical properties of the proximal femur [4]. Both the 
structural and biomechanical properties of the proximal femur are critically determined by the 
bone geometry, which refers to the distribution and alignment of bone tissue [5]. However, the 
complex structure and bone density distribution in this region make three-dimensional (3D) 
analysis of the proximal femur difficult. 
One clinically useful approach for assessing BMD and bone geometry is hip structure 
analysis (HSA) [6] based on dual-energy X-ray absorptiometry (DXA) data and 
biomechanical indices [7]. However, because most of the geometrical parameters of HSA 
depend on assumptions about the shape of the cross-section and on fixed percentages of 
cortical bone, and because all of the geometrical parameters are derived from bone density [8], 




have employed HSA to examine the longitudinal effects of anti-osteoporotic agents [9-12]. 
Furthermore, poor accuracy and precision of hip DXA measurement is inevitable in cases 
where the femoral neck is short and in cases where it is difficult to maintain the inner rotation 
of the hip joint [13]. Computed tomography (CT) measurement, on the other hand, is 
convenient and useful in that the femoral dimensions can be adjusted during image 
processing. 
Quantitative computed tomography (QCT) has become an increasingly useful clinical 
research tool for measuring volumetric BMD (vBMD) and analyzing hip geometry [14-17]. 
CT-based HSA provides geometrical parameters independent of BMD, and has the advantage 
of being able to evaluate the cortex separately. However, only one study has employed CT to 
examine the effects of drugs on the 3D geometrical parameters of the proximal hip [18]. 
Eldecalcitol (ELD) is a vitamin D analog that has a hydroxypropoxy substituent at the 
2β-position of 1,25-dihydroxyvitamin D3. In a phase II randomized, placebo-controlled, 
double-blind clinical trial for osteoporotic subjects with sufficient vitamin D supply, ELD 
treatment for 12 months significantly increased BMD of the lumbar spine and hip in a 
dose-dependent manner [19]. Further, a recent phase III randomized, active comparator, 
double blind study to compare the effects of 144 weeks’ ELD treatment and 144 weeks’ 
alfacalcidol (ALF) treatment on osteoporotic fracture has demonstrated the superior 
anti-fracture efficacy of ELD [20]. The clinical effect of ALF in preventing vertebral fractures 
has been reported [21]. Although the effects of ALF on bone geometry and strength of the 
proximal femur have not been established in humans, the effects of ALF on cortical bone 
have been reported in animal studies using ovariectomized or aged rats [22,23]. 
The purpose of the present study is to evaluate the effects of ELD versus ALF on BMD, 
bone geometry, and biomechanical properties of the proximal femur by using clinical 
multidetector-row CT (MDCT) in a subgroup of the phase III randomized clinical trial, and to 




2.  SUBJECTS AND METHODS 
2.1  Subjects 
The subjects were 193 ambulatory patients with osteoporosis (189 postmenopausal women 
and 4 men; age range: 52–85 years, average±SD: 70.9±6.92 years), who represent a subgroup 
of a randomized, active comparator, double-blind study to compare the anti-fracture efficacy 
of ELD with that of ALF in 1054 subjects (1030 women and 24 men, aged from 46 to 92 
years, mean age: 72.1 years) enrolled at 52 medical centers in Japan [20]. In that study, 
subjects were randomly assigned to receive either 0.75 µg ELD [19] or 1.0 µg ALF once daily 
for 144 weeks. This trial is registered with ClinicalTrials.gov, number NCT00144456. The 
protocol was approved by the internal human studies review board at each center, and written 
informed consent was obtained from each patient. 
The proximal femur of the 193 subjects was scanned with MDCT at 11 institutions to 
measure hip BMD, bone geometry, and biomechanical indices. We did not intentionally select 
the subjects. Since not all institutes had an MDCT scanner, the 193 subjects were those 
examined and treated in hospitals which had MDCT scanners. All subjects in this study fulfilled 
the inclusion criteria of the original study. In brief, in the original study, subjects without 
vertebral fractures were enrolled if their lumbar spine or total hip BMD T-score was below 
–2.6 and they were over 70 years, or if their T-score was below –3.4 and they were below 70 
years. Patients with lumbar spine or total hip BMD T-score of below –1.7 were enrolled if 
they had between one and five vertebral fractures. Prevalent vertebral fractures at enrolment 
were assessed by lateral spine X-ray examination of the thoracic and lumbar vertebrae, and 
were diagnosed quantitatively according to the criteria of the Japanese Society for Bone and 
Mineral Research (JSBMR) [24]. Women were at least 3 years after menopause or more than 
60 years of age, and men were over 60 years. Patients were excluded if they had primary 
hyperparathyroidism, Cushing’s syndrome, premature menopause due to hypothalamic, 




other causes of secondary osteoporosis, or had a history of urolithiasis. Patients were also 
excluded if they had taken any oral bisphosphonates within 6 months before entry or for more 
than 2 weeks during the period 6 to 12 months before entry, or intravenous bisphosphonates at 
any time; had taken glucocorticoids, calcitonin, vitamin K, active vitamin D compounds, 
raloxifene, or hormone replacement therapy within the previous 2 months; had serum Ca 
levels of above 10.4 mg/dL (2.6 mmol/L) or urinary Ca excretion of over 0.4 mg/dL 
glomerular filtrate (GF)(0.1 mmol/L GF); had serum creatinine above 1.3 mg/dL (115 
µmol/L); or had clinically significant hepatic or cardiac disorders. 
3.  Methods 
3.1  CT data acquisition 
CT data was acquired at baseline and at completion of 144 weeks of treatment, using the 
following scanning and reconstruction protocol. 
The scanning conditions (X-ray energy: 120–140 kV; X-ray current: 200–300 mA; 
rotation speed: 0.8–1.0 sec/rot; beam pitch: 0.5625–0.9375) and reconstruction parameters 
were predefined for each type of CT scanner (see Appendix). Beam pitch is defined as the 
ratio of table feed per rotation to the collimation, where collimation is the product of 
slice-thickness and the number of slices in each rotation. Beam pitch was kept under 1.0 
except for one CT scanner (Somatom Plus 4 Volume Zoom). Field of View (FOV) was 
defined as 350 mm to cover both hip regions. In-plane spatial resolution of 0.625–0.652 mm 
and reconstructed slice thickness of 0.500–0.625 mm was adjusted according to CT scanner 
type (see Appendix). The CT values were converted to bone mineral scale by using a solid 
reference phantom, B-MAS200 (Fujirebio Inc., Tokyo, Japan), containing hydroxyapatite 
(HA) at 0, 50, 100, 150, and 200 mg/cm3. For all of the CT data, a constant threshold value of 
350 mg/cm3 was used to define the cortical bone. 
The MDCT scanners used in this study originally included four Asteion 4 scanners, one 




Corporation,Tochigi, Japan); one LightSpeed Ultra_8 scanner, and one LightSpeed Plus_4 
scanner (GE-Yokogawa Medical,Tokyo,Japan); and one Somatom Plus 4 Volume Zoom 
scanner (Siemens, AG, Berlin and Munich, Germany). In two institutions, CT scanners were 
changed during the trial period (from Aquilion 16 to Aquilion 64, and from LightSpeed 
Plus_4 to LightSpeed Ultra_16); therefore, the pairs of CT data in 26 patients were obtained 
using different CT scanners. However, because the results of all patients did not differ from 
results excluding the 26 patients (data not shown), the results of all patients are presented in 
this article. 
Good linear correlations between the CT values and HA concentrations were 
demonstrated (r = 0.996–0.999; p < 0.0002–0.05) in all CT scanners. Differences in CT 
values according to X-ray energy were corrected by using the reference phantom to convert 
CT values to HA equivalent values. However, it was necessary to confirm the longitudinal 
stability of the CT values of the threshold value used to define the cortical bone. For the rod 
containing 200 mg/cm3 HA equivalent, which was used as the threshold value to define the 
cortical region, there was less than 0.01% difference between the baseline CT value and CT 
value at 144 weeks. 
3.2  Positioning of patients for CT scanning 
The subjects were scanned in the supine position, with the reference phantom beneath the 
patient and placed so as to cover a region from the top of the acetabulum to 5 cm below the 
bottom of the lesser trochanter in each hip joint (average slice number was 298). Bolus bags 
were placed between the subject and the CT calibration phantom. Both feet were fixed using a 
custom-made adjuster for hip DXA, which kept the subject’s knees flat and the toes pointed 
inward. The subject’s hands and arms were placed over the subject’s head or as high on the 
chest as was comfortable to avoid interfering with the scan area. The CT scanner table height 




3.3  Analysis of BMD, bone geometry, and biomechanical properties obtained by CT 
3.3.1  Analysis of CT data  
Patient data were evaluated with QCT-Pro software v4.1.3 with the QCT-Pro Bone 
Investigational Toolkit v2.0 (BIT) (Mindways Software,Austin,USA) and also with Real 
Intage visualization software (KGT,Tokyo,Japan) based on 3D DICOM data to provide fusion 
functions and several geometrical measurements. All measurements were analyzed by a 
radiologist (M. Ito) blinded to treatment group assignment. 
3.3.1.1  QCT-Pro CTXA hip exam analysis 
The exact 3D rotation of the femur and the threshold setting for defining the bone contours 
appeared to be the two most critical steps for achieving accuracy and reproducibility in the 
automated procedures performed by QCT-Pro. The outer cortical BMD thresholds had to be 
adapted individually for each scan. 
The femoral neck axis was identified visually and also automatically with the “Optimize 
FN Axis” algorithm. QCT-Pro BIT processing was then performed with a fixed bone 
threshold for cortical separation set to 350 mg/cm3 for all patients and visits. 
This application was used to measure hip axis length (HAL), femoral neck angle (FNA), 
and neck width. vBMD, cross-sectional area (CSA), and cross-sectional bone mass of the 
femoral neck (total, cortical, and trabecular region), as well as cortical thickness and cortical 
perimeter were also measured. Trabecular parameters in each subject were calculated based 
on the total and cortical parameters. Biomechanical properties were also derived from the 
cross-sectional parameters of the femoral neck. 
3.3.1.2  Real Intage analysis 
This comprehensive image data visualization software based on 3D DICOM data provides 
fusion functions and several geometrical measurements. For bone analysis of the femoral 




to define the same regions of interest. The software was then used to measure the outer 
perimeter, inner perimeter, bone area, cortical bone density, and cross-sectional moment of 
inertia (CSMI) of the femoral shaft. 
3.3.2  Analysis of cross-sectional volumetric BMD and bone geometry of the femoral neck 
The cross-sectional femoral neck data were derived on the basis of the geometrical axis to 
calculate volumetric total BMD (total vBMD; mg/cm3), cortical BMD (cortical vBMD; 
mg/cm3), trabecular BMD (trabecular vBMD; mg/cm3), total CSA (cm2), cortical CSA (cm2), 
trabecular CSA (cm2), total bone mass (g), cortical bone mass (g), and trabecular bone mass 
(g). Cortical thickness (mm) and cortical perimeter (mm) were also derived. 
These parameters were all calculated with QCT-Pro. 
3.3.3  Biomechanical parameters of the femoral neck 
Because biomechanical parameters were determined on the principal axis, the cross-sectional 
moment of inertia (CSMI; mm4), the section modulus (SM; mm3), and buckling ratio (BR) 
were calculated from bone density and geometrical data. The CSMI is defined by the 
integration of products of incremental cross-sectional area and the square of their distance 
from the center of mass (centroid). The SM is the ratio of CSMI to the maximal distance of 
the material from the centroid, which is directly related to the strength with respect to a 
corresponding bending stress. For very thin-walled bones, failure occurs on the compressive 
surface due to local buckling, which is estimated as BR; this was calculated in this study as 
the average distance from the centroid divided by the average cortical thickness. 
These parameters were calculated with QCT-Pro. 
3.3.4  Analysis of vBMD, bone geometry, and biomechanical properties of the femoral shaft 
Using the Real Intage program, image fusion was performed between the baseline image and 




in the region of the femoral shaft from 2 to 4 cm below the bottom of the lesser trochanter. 
The threshold value to discriminate the cortical region was defined as the CT value 
corresponding to 200 mg/cm3 HA in the reference phantom. In the femoral shaft, average 
cortical density (Co.vBMD; mg/cm3), total area (T.AR; mm2), bone area (B.AR; mm2), 
cortical outer perimeter (OUT.PERI; mm), cortical inner perimeter (INN.PERI; mm), and 
cross-sectional moment of inertia (CSMI; mm4) were measured. 
Reproducibility of the analysis by the QCT-Pro program was calculated by using five 
repeated measurements with visual matching each time from CT data sets without visible 
artifacts from seven healthy subjects. The coefficient of variation (%), as determined by the 
root mean square standard deviation divided by the mean, was 1.49% for total vBMD, 2.63% 
for cortical vBMD, 1.12% for total mass, 1.71% for total area, 2.11% for cortical area, 2.11% 
for cortical perimeter, and 3.58% for cortical thickness in the femoral neck [25]. In the 
analysis of the femoral shaft using Real Intage, the coefficient of variation was 0.53% for 
cortical vBMD, 0.52% for total area, 0.80% for bone area, 1.52% for outer perimeter, and 
2.22% for inner perimeter. Since the %CVs of the others were similar, we did not present 
them all. 
 
3.4  Statistics 
All randomized patients who had been administered one of the drugs and who had been 
assessed both at baseline and at 144 weeks were included in the analysis. 
Student’s t-tests were used to determine the significance of differences between the ALF 
and ELD groups. Paired t-tests were used to determine the significance of difference from the 
baseline. 
All p values calculated in the analysis were two-sided and were not adjusted for multiple 




Statistical analyses were done with SAS version 8.2 (SAS Institute,Cary USA). 
4.  RESULTS 
Table shows the demographic and bone characteristics of the subjects at baseline. None of the 
parameters differed significantly between the ALF and ELD groups. 
4.1  Cross-sectional geometry and vBMD of the femoral neck 
In the femoral neck, we measured cross-sectional cortical thickness and perimeter, as well as 
the total, cortical, and trabecular vBMD, CSA, and bone mass (Fig. 1). Cortical thickness of 
the femoral neck decreased significantly from baseline in the ALF group (–4.54±7.72%, p < 
0.001), while it did not significantly change in the ELD group; as a result, the percentage 
change in cortical thickness differed significantly between the ELD and ALF groups (p = 
0.042). Cortical perimeter increased significantly from baseline in both the ELD group 
(2.63±7.52%, p = 0.008) and the ALF group (3.86±6.28%, p < 0.001). Thus, although there 
was no significant difference between the effects of the two drugs on the increased cortical 
perimeter, ELD prevented the decrease in cortical thickness. 
Cortical vBMD of the femoral neck increased significantly in both the ELD group 
(1.82±4.78%, p = 0.004) and the ALF group (2.21±4.98%, p < 0.001), with no difference 
between the two groups (Fig. 1). Trabecular vBMD of the femoral neck significantly 
decreased in both the ALF group (–7.49±8.82%, p < 0.001) and the ELD group (–3.99±7.83%, 
p < 0.001), and there was a significant difference between the two groups (p = 0.020). Total 
vBMD of the femoral neck decreased from baseline in the ALF group (–2.25±5.32%, p < 
0.001), whereas it was maintained in the ELD group. Accordingly, the percentage changes in 
total vBMD differed significantly between the ELD and ALF groups (p = 0.009). 
Regarding cortical CSA, the ELD group showed a non-significant trend for an increase 
(1.73±7.62%, p = 0.082) and the ALF group showed a non-significant trend for a decrease 




CSA showed a significant difference between the ELD and ALF groups (p = 0.031). 
Trabecular CSA of the femoral neck increased significantly in the ALF group (2.92±7.74, p = 
0.003), but not in the ELD group (1.92±7.61%, p = 0.054). Total CSA increased from the 
baseline in both the ELD group (1.69±6.78%, p = 0.056) and the ALF group (1.51±5.77%, 
p = 0.039), with no difference between the two groups. 
Cortical bone mass of the femoral neck increased significantly from baseline in both the 
ELD group (3.68±7.51%, p < 0.001) and the ALF group (2.45±9.64%, p = 0.045) (Fig. 1). 
Total bone mass of the femoral neck increased significantly only in the ELD group (1.93±5.89, 
p = 0.013). Trabecular bone mass significantly decreased in the ALF group (–3.96±9.39, p < 
0.001), whereas it did not change from baseline in the ELD group, and there was no 
significant difference between the two groups (p = 0.268). Thus, in the ELD group, both total 
and cortical bone mass increased from baseline, and trabecular bone mass was maintained. 
4.2  Biomechanical properties of the femoral neck 
Biomechanical properties (CSMI, SM, and BR) of the femoral neck were compared between 
the ELD group and the ALF group (Fig. 2). CSMI and SM improved significantly in the ELD 
group (5.30±11.56%, p < 0.001 for CSMI; 4.33±11.92%, p = 0.006 for SM), whereas these 
parameters did not change in the ALF group. Thus, there were significant differences between 
the ELD and ALF groups in the percentage changes of CSMI and SM from baseline (p = 
0.037 and p = 0.023, respectively). Although BR increased from the baseline in both treatment 
groups (3.76±11.33%, p = 0.012 in ELD; 7.44±9.43%, p < 0.001 in ALF), the increase was 
significantly less in the ELD group than in the ALF group (p = 0.049) (Fig. 2). Collectively, 
these results suggest that ELD maintained the biomechanical properties of the femoral neck 
more effectively. 
4.3  Geometry, vBMD, and biomechanical properties of the femoral shaft 
The percentage changes in BMD, bone geometry, and biomechanical properties in the femoral 




the shaft decreased significantly in both the ELD group (–10.13±4.54%, p < 0.001) and the 
ALF group (–11.85±4.58%, p < 0.001) (Fig. 3); however, the percentage decrease was 
significantly smaller in the ELD group than in the ALF group (p = 0.026). Although the total 
area increased significantly from baseline in both the ELD and ALF groups, the bone area of 
the femoral shaft increased significantly only in the ELD group (1.75±3.24%, p < 0.001). 
Outer perimeter increased significantly from baseline in both treatment groups 
(0.92±1.67%, p < 0.001 in ELD; 0.94±2.22%, p < 0.001 in ALF), with no difference between 
the two groups. Inner perimeter increased significantly in both groups (0.76±2.75%, p = 0.023 
in ELD; 1.85±3.52%, p < 0.001 in ALF); however, the percentage increase was significantly 
greater in the ALF group than in the ELD group (p = 0.042). CSMI in the femoral shaft 
increased significantly from baseline in both the ELD and ALF groups. Thus, although there 
was no difference between groups with respect to this biomechanical parameter, the increase 
in inner perimeter, presumably due to accelerated resorption, was more effectively prevented 
by ELD. 
5.  DISCUSSION 
A recent randomized, double-blind study to compare the effects of ELD with ALF 
demonstrated the superiority of ELD over the active comparator, especially with respect to 
non-vertebral fractures [20]. In order to gain insight into the biomechanical basis underlying 
this clinically verified anti-fracture action of ELD, we took a subgroup of the randomized 
study and used clinical MDCT scanning to compare the effects of ELD and ALF on the 3D 
structure of the proximal femur, focusing particularly on the cortical component and 
biomechanical properties. Our study not only revealed the distinct action of ELD on the 
cortical compartment but also provided evidence for the improvement of biomechanical 
properties. 
In the femoral neck, whereas cross-sectional cortical thickness decreased in the ALF 




perimeter increased in both the ALF and ELD groups, it is suggested that ELD was more 
effective than ALF in countering endocortical bone resorption, thereby maintaining cortical 
thickness. This is also consistent with the trend for increased CSA by ELD. Figure 4 
schematically illustrates the distinct actions of ELD and ALF on the cortical geometry and 
density of the femoral neck and shaft. 
As bone resorption accelerates with aging, especially from the inner surface of the cortex, 
the endocortical compartment tends to become trabeculated, and therefore represents an 
important target site for intervention. A possible mechanism of action of ELD is to reduce the 
number of pores opening through the endocortical surface, thereby maintaining cortical 
thickness and increasing cortical density. ALF treatment, on the other hand, failed to block the 
resorption of trabeculated endocortical bone, resulting in an expansion of the trabecular bone 
marrow cavity, decreased trabecular BMD, reduced cortical thickness, and increased cortical 
density. As a result of the ELD-specific effect on the endocortical surface, it is conceivable 
that ELD was more effective in increasing cortical bone mass than ALF. This observation is 
supported by the significantly higher reduction of bone resorption biomarkers observed with 
ELD treatment than with ALF treatment (data not shown). 
Regarding the increased cortical perimeter in both the ALF and ELD groups, it is difficult 
to determine whether this simply reflects the age-related increase in periosteal apposition or 
whether the drugs in fact had some positive effect in extending bone perimeter. A recent QCT 
study on 2 years’ treatment with teriparatide [18] failed to reveal increases in total CSA or 
periosteal apposition. Although direct comparison is not feasible, given the difference in the 
observation period (2 versus 3 years) and presumably also in the threshold value to define the 
cortical bone, the significant increases in cortical perimeter after 3 years’ treatment with ELD 
as well as ALF may imply that ELD and ALF have the potential to stimulate bone apposition 
at the periosteal surface. 
Along with these changes in the 3D geometry of the femoral neck, ELD, but not ALF, 




compared the features of the femoral neck geometry in patients with hip or trochanteric 
fractures with their controls; patients with femoral neck fracture had a significantly longer 
HAL, lower CSMI, and higher BR, while those with trochanteric fracture had a smaller 
cortical CSA of the femoral neck. In view of the present findings that ELD increases CSMI 
and perhaps cortical CSA as well, ELD is expected to have the potential to reduce the risk of 
both femoral neck and trochanteric fractures. 
ALF and ELD failed to decrease BR. BR is a secondary parameter calculated by the 
average distance to the center of mass divided by average cortical thickness, and it is 
employed as a means to estimate the stability of the cortex in thin-walled regions subject to 
bending. Our previous study [26], in which BR was calculated according to the same formula, 
demonstrated that the BR in patients with hip fracture (12.22±1.69) was higher than that in the 
control group (8.32±2.13). In the present study, the percentage increase in BR during the 
3-year follow-up was smaller in the ELD group (0.48%/year; 8.92±2.18 at baseline and 
9.21±2.28 at 144 weeks) than in the ALF group (2.55%/year; 9.21±2.36 at baseline and 
9.90±2.71 at 144 weeks). In view of our previous results on BR [25], calculated by the same 
formula, that the longitudinal change in BR of healthy post-menopausal women younger than 
the subjects in this study was 1.48±4.81% per year, it is tempting to speculate that ELD may 
have countered the age-related increase in BR. 
The bone geometry and vBMD of the femoral shaft were examined using an analytical 
program different from that used to examine the femoral neck. Although it is difficult to 
compare values obtained using different software, we reasoned that comparison of the results 
by the percentage changes should be acceptable. T.AR and B.AR in the femoral shaft 
correspond respectively to total and cortical CSAs of the femoral neck, and OUT.PERI 
corresponds to cortical perimeter of the femoral neck. The results (Fig. 3) indicate that the 
changes in geometry of the femoral shaft were very consistent with the features in the femoral 
neck. Total CSA of the femoral neck increased in both the ALF and ELD groups (Fig. 1), as 




in the ELD group (Fig. 3), and cortical CSA of the femoral neck increased more in the ELD 
group (Fig. 1). OUT.PERI of the femoral shaft increased in both the ALF and ELD groups 
(Fig. 3), as did the cortical perimeter of the femoral neck (Fig. 1). 
Notably, the cortical vBMD of the femoral neck increased in both the ALF and ELD 
groups, whereas the cortical vBMD of the femoral shaft decreased in both groups. Since the 
cortex in the femoral neck is very thin compared to that in the shaft, the partial-volume effect 
should be taken into account when evaluating the cortical vBMD of the femoral neck. 
However, according to our previous study on age-related changes in the femoral neck and 
shaft in non-osteoporotic subjects [25], the rate of decrease in cortical vBMD was greater in 
the femoral shaft than in the femoral neck. It is possible, therefore, that ALF and ELD failed 
to prevent the rapid decline in cortical density of the femoral shaft. 
Finally, the present study has limitations. First, the study lacked a placebo group. Second, 
because our study included very few cases of hip fracture (only one in each group), the 
relationship of ALF or ELD treatment with the incidence of hip fracture has not been verified. 
In conclusion, our longitudinal analysis of hip geometry by clinical CT has revealed the 
advantage of ELD over ALF in maintaining cortical thickness and vBMD of the femoral neck 
and shaft, probably through mitigating endocortical bone resorption, thereby improving the 
biomechanical parameters. By maintaining the biomechanical properties of the proximal 
femur, ELD may have the potential to reduce the risk of hip fracture. 
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Figure 1  Eldecalcitol maintains cortical thickness and increases volumetric BMD and 
bone mass in cortex of femoral neck 
Values are percentage changes from baseline (mean±SD) in cross-sectional bone geometry 
and vBMD in the femoral neck for groups treated with alfacalcidol (blue bars) and 
eldecalcitol (red bars). 
*p < 0.05, **p < 0.01, ***p < 0.001 
vBMD: volumetric bone mineral density 





Figure 2  Eldecalcitol improves biomechanical properties of the femoral neck 
Cross-sectional moment of inertia (CSMI), section modulus (SM), and buckling ratio (BR) 
were calculated in the femoral neck, and percentage changes from baseline (mean±SD) are 
shown for the alfacalcidol group (blue bars) and the eldecalcitol group (red bars). 





Figure 3  Effects of eldecalcitol on bone geometry and biomechanical properties of the 
femoral shaft 
Percentage changes from baseline (mean±SD) in vBMD, bone geometry, and biomechanical 
properties in the femoral shaft are shown for the alfacalcidol group (blue bars) and the 
eldecalcitol group (red bars). 
Co.vBMD: cortical volumetric bone mineral density; T.AR: total area; B.AR: bone area; 
OUT.PERI: outer perimeter; INN.PERI: inner perimeter; CSMI: cross-sectional moment of 
inertia. 





Figure 4  Schematic illustration of the effects of eldecalcitol (ELD) vs. alfacalcidol 
(ALF) on the cortical geometry and density of the femoral neck and shaft 
In the femoral neck, compared with baseline, the effects of ALF and ELD on the cortical 
perimeter (i.e., periosteal apposition) are similar. However, ELD counters endocortical 
resorption more effectively than ALF, which is reflected by the increased cortical thickness, 
thereby leading to improved biomechanical properties, represented by section modulus (SM). 
In the femoral shaft, ALF and ELD have similar effects, except that ELD decreases cortical 
density less than ALF, and increases inner cortical perimeter less than ALF. 




 A new vitamin D analog, Eldecalcitol, on hip geometry and biomechanical 
properties by clinical CT, in comparison with Alfacalcidol 
 Eldecalcitol increases cortical area, mineral density, and bone mass, and 
maintains cortical thickness  
 Eldecalcitol is also more potent in mitigating endocortical bone resorption 
than Alfacalcidol 
 By improving the biomechanical properties of proximal femur, Eldecalcitol 
may have the potential to reduce the risk of hip fractures 
